Adlai Nortye (ANL) Accumulated Expenses (2022 - 2025)
Adlai Nortye (ANL) reported Accumulated Expenses of $3.1 million for Q4 2025, up 2.64% year-over-year from $3.1 million in Q4 2024, and up 2.64% on a QoQ basis from $3.1 million in Q4 2024.
Adlai Nortye (ANL) has 4 years of Accumulated Expenses data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Accumulated Expenses rose 2.64% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (up 2.64% YoY) and the FY2025 annual result came in at $3.1 million, up 2.64% from the prior year.
- Accumulated Expenses climbed to $3.1 million in Q4 2025 per ANL's latest filing, from $3.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.8 million in Q4 2023 and bottomed at $3.1 million in Q4 2024.
- The 4-year median for Accumulated Expenses is $3.4 million (2022), against an average of $3.4 million.
- The widest annual swing landed in 2023, when Accumulated Expenses gained 5.3%; it then slipped 19.69% in 2024.
- Tracing ANL's Accumulated Expenses over 4 years: stood at $3.6 million in 2022, then advanced by 5.3% to $3.8 million in 2023, then dropped by 19.69% to $3.1 million in 2024, then advanced by 2.64% to $3.1 million in 2025.
- Per Business Quant, the three latest ANL Accumulated Expenses figures stand at $3.1 million (Q4 2025), $3.1 million (Q4 2024), and $3.8 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.14 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Dec 31, 2022 | 3.62 Mn |